ARDM Aradigm Corporation

0.47
-0.04  -8%
Previous Close 0.51
Open 0.46
Price To Book -0.3
Market Cap 7103077
Shares 15,219,793
Volume 152,150
Short Ratio
Av. Daily Volume 161,700

SEC filingsSee all SEC filings

  1. S-1 - General form for registration of securities under the Securities Act of 1933 181212039
  2. RW - Registration Withdrawal Request 181205127
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181187037
  4. 8-K - Current report 181186671
  5. 8-K - Current report 181163810

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval granted July 16, 2009.
Sumavel
Migraine
Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval. CRL announced January 29, 2018 - two-year additional Phase 3 trial requested by FDA.
Linhaliq (Pulmaquin)
Non-cystic fibrosis bronchiectasis (non-CF BE).

Latest News

  1. Aradigm: 3Q Earnings Snapshot
  2. Aradigm Announces Third Quarter 2018 Financial Results
  3. Consolidated Research: 2018 Summary Expectations for Community Health, Aradigm, Avnet, Sanchez Energy, Black Stone Minerals, and Navient — Fundamental Analysis, Key Performance Indications
  4. Aradigm Announces Second Quarter 2018 Financial Results
  5. Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Directors
  6. Aradigm Announces First Quarter 2018 Financial Results
  7. Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis
  8. Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission
  9. Aradigm reports 4Q loss
  10. Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results
  11. DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm
  12. FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aradigm Corporation (ARDM) & Lead Plaintiff Deadline: March 12, 2018
  13. Aradigm Files MAA for Bronchiectasis Candidate in the EU
  14. The Klein Law Firm Reminds Shareholders of Aradigm Corporation of a Class Action and a Lead Plaintiff Deadline of March 12, 2018 (ARDM)

SEC Filings

  1. S-1 - General form for registration of securities under the Securities Act of 1933 181212039
  2. RW - Registration Withdrawal Request 181205127
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181187037
  4. 8-K - Current report 181186671
  5. 8-K - Current report 181163810
  6. 8-K - Current report 181154634
  7. 8-K - Current report 181147790
  8. 8-K - Current report 181074012
  9. 8-K - Current report 181062808
  10. 8-K - Current report 181023868